Gene · 9340
Papers528
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1 to 20 of 528
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Integrative predictive modelling and multi-omics validation reveals potential indicators of clinical heterogeneity in HCC. | Biochem Biophys Res Commun | 2026 | 42759273 | PubTator, text mining | PubMed |
| EVIDENCE OF THE INFLUENCE OF GLUCAGON-LIKE PEPTIDE ANALOGS IN INFLAMMATORY BOWEL DISEASE: A SCOPING REVIEW. | Arq Gastroenterol | 2026 | 42615757 | PubTator, text mining | PubMed |
| Integrative Analysis of Steroid Metabolism-Based Molecular Subtypes Reveals Prognostic Subtypes and Therapeutic Implications in Gastric Cancer. | Cancer Inform | 2026 | 42571211 | PubTator, text mining | PubMed |
| Genetic architecture and cross-platform validation of apolipoprotein A-IV concentrations. | Genome Biol | 2026 | 42449406 | PubTator, text mining | PubMed |
| Glucagon-Like Peptide-2 Receptor: A Master Integrator of Gut-Brain-Liver Communication in Metabolic and Cognitive Health. | Compr Physiol | 2026 | 41943399 | PubTator, text mining | PubMed |
| Exosome-like nanovesicles from acerola for CRISPR-Cas9 ribonucleoprotein delivery to the central nervous system. | Mol Ther Nucleic Acids | 2026 | 41909467 | PubTator, text mining | PubMed |
| Bispecific GLP-1/GLP-2 agonism in advanced type 2 diabetes: preclinical characterization and a randomized, double-blind, placebo-controlled phase I trial. | Nat Commun | 2026 | 41876542 | PubTator, text mining | PubMed |
| Dapiglutide, a dual GLP-1 and GLP-2 receptor agonist, for obesity: a randomised, double-blind, placebo-controlled parallel-group, proof-of-concept trial. | EClinicalMedicine | 2026 | 41768273 | PubTator, text mining | PubMed |
| Identification and Functional Validation of PTH2R as a Therapeutic Target in Lung Adenocarcinoma. | Biomedicines | 2026 | 41751388 | PubTator, text mining | PubMed |
| DNA methylation-mediated silencing of MEOX1 promotes glycolysis and immune evasion in colorectal cancer cells through inhibition of GLP2R transcription. | Cell Biosci | 2026 | 41612494 | PubTator, text mining | PubMed |
| Gut Peptide Alterations in Type 2 Diabetes and Obesity: A Narrative Review. | Curr Obes Rep | 2026 | 41575482 | PubTator, text mining | PubMed |
| GLP-2 alleviates postmenopausal osteoporosis by acting on osteoblasts through the PI3K/AKT/FOXO1 signalling pathway to downregulate FGF23 expression. | J Orthop Surg Res | 2026 | 41572358 | PubTator, text mining | PubMed |
| Microbial activation of the GLP-2R mitigates gastrointestinal inflammation. | Nat Commun | 2026 | 41540065 | PubTator, text mining | PubMed |
| Global glucagon-like peptide-2 receptor activation linked to increased obesity risk in the UK Biobank. | Metabolism | 2026 | 41519224 | PubTator, text mining | PubMed |
| Rare coding mutations in the glucagon-like peptide-2 pathway are associated with increased risk of binge eating disorders. | Behav Brain Res | 2026 | 41248737 | PubTator, text mining | PubMed |
| Three-year experience with GLP-2 analog in intestinal rehabilitation for pediatric-onset short bowel syndrome. | Pediatr Surg Int | 2025 | 40875041 | PubTator, text mining | PubMed |
| Effects of Proanthocyanidins on Growth Performance, Intestinal Inflammation and Barrier Function, and Bile Acid Metabolism-Related Genes in Weaned Piglets Challenged with Lipopolysaccharide. | Animals (Basel) | 2025 | 40646724 | PubTator, text mining | PubMed |
| The central signaling pathways related to metabolism-regulating hormones of the gut-brain axis: a review. | J Transl Med | 2025 | 40500780 | PubTator, text mining | PubMed |
| Development of a Mechanism of Action-Reflective Cell-Based Reporter Gene Assay for Measuring Bioactivities of Therapeutic Glucagon-like Peptide-2 Analogues. | Molecules | 2025 | 40363720 | PubTator, text mining | PubMed |
| Development of a prognostic risk model for colorectal cancer and association of the prognostic model with cancer stem cell and immune cell infiltration. | J Gastrointest Oncol | 2025 | 40115909 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/9340/papers